+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects



The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects



American Journal of Respiratory and Critical Care Medicine 155(6): 1828-1834



A humanized murine monoclonal antibody directed to the Fc epsilonR1-binding domain of human IgE (rhuMAb-E25) has been shown to inhibit the binding of IgE to mast cells without provoking mast cell activation. To examine the effects of neutralizing IgE on allergic airway responses, we assessed the effects of 9 wk of treatment with rhuMAb-E25 in a parallel group, randomized, double-blind, placebo-controlled study of 19 allergic asthmatic subjects. We found that treatment with rhuMAb-E25 reduced serum IgE, increased the dose of allergen needed to provoke an early asthmatic response, reduced the mean maximal fall in FEV1 during the early response (30 +/- 10% at baseline to 18.8 +/- 8%, versus 33 +/- 8% at baseline to 34 +/- 4% after placebo; p = 0.01), and reduced the mean maximal fall in FEV1 during the late response (24 +/- 20% at baseline to 9 +/- 10% versus 20 +/- 17% at baseline to 18 +/- 17% after placebo; p = 0.047). We conclude that an anti-IgE monoclonal antibody, which inhibits binding of IgE to its receptor, suppresses the early- and late-phase responses to inhaled allergen in allergic asthmatic subjects. Targeting IgE with rhuMAb-E25 might be a useful treatment for allergic asthma.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009559889

Download citation: RISBibTeXText

PMID: 9196082

DOI: 10.1164/ajrccm.155.6.9196082


Related references

Effect of repeated doses of inhaled heparin on allergen-induced early and late asthmatic responses in atopic asthmatic subjects. European Respiratory Journal 8(SUPPL 19): 10S, 1995

Urinary leukotriene E4 levels during early and late responses to allergen in asthmatic subjects. European Respiratory Journal 7(SUPPL 18): 458S, 1994

Effect of salmeterol on eosinophil count in induced sputum after late airway response to allergen inhalation in asthmatic subjects. European Respiratory Journal Supplement 9(23): 136S, 1996

Blood markers of early and late airway responses to allergen in asthmatic subjects. Relationship with functional findings. Allergy 52(1): 32-40, 1997

Site of airflow obstruction during early and late phase asthmatic responses to allergen bronchoprovocation. Chest 88(3): 369-375, 1985

Plasma and urinary histamine in allergen-induced early and late phase asthmatic responses. European Respiratory Journal 6(8): 1138-1144, 1993

Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 160(3): 1023-1027, 1999

Comparison in the same asthmatic subjects of airway responses to exercise and allergen inhalation. European Journal Of Clinical Investigation: 322-323, 1976

Pranlukast , a leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsivness in asthmatic subjects. European Respiratory Journal Supplement 10(25): 419S, Sept, 1997

Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 52(4): 348-354, 1997

Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 156(6): 1738-1745, 1997

Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. Journal of Allergy & Clinical Immunology 102(2): 177-183, 1998

Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine*1. Journal of Allergy and Clinical Immunology 79(5): 734-740, 1987

Comparative effects of inhaled salbutamol sodium cromoglycate and beclomethasone dipropionate on allergen induced early asthmatic responses late asthmatic responses and increased bronchial responsiveness to histamine. Journal of Allergy & Clinical Immunology 79(5): 734-740, 1987

Effect of a 5 lipoxygenase 5 lo inhibitor a 64077 on allergen induced early and late asthmatic responses. American Review of Respiratory Disease 141(4 PART 2): A32, 1990